Personalized antibiotic spray aims to stop deadly pneumonia in ICU patients
NCT ID NCT07463339
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tests whether rapid analysis of the airway microbiome can guide inhaled antibiotics to prevent ventilator-associated pneumonia (VAP) in ICU patients. 70 adults on ventilators will receive either microbiome-guided inhaled antibiotics or a placebo for up to 5 days. The goal is to see if this personalized prevention strategy is feasible and safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- inhaled antibiotics (tobramycin, aztreonam, vancomycin)
- What this could lead to
- If successful, this approach could reduce pneumonia rates in ventilated ICU patients by targeting antibiotics to those most likely to benefit.
- What could go wrong
- This is a small pilot study (70 people) testing feasibility, not yet proven to prevent pneumonia. Inhaled antibiotics may cause side effects or not work as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRITICAL ILLNESS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI may predict transfusion needs to shield ICU patients from organ failure
- A simple blood test trend may flag ICU patients at risk
- Could a simple CT scan reveal which ICU cancer patients are at highest risk?
- A gentle touch from family may calm the ICU storm
- A Mother's voice as medicine? trial tests comforting effect on ventilated children
- Could lung fluid proteins reveal a new way to track severe lung injury?